|Place of Origin:||China|
|Minimum Order Quantity:||1KG|
|Packaging Details:||Aluminum foil bag|
|Payment Terms:||L/C, D/A, D/P, T/T, Western Union, MoneyGram，Alibaba Assurance Order|
|Other Name:||DMMPA||Appearance:||White Crystalline Powder|
99% AD Medicine Grade DMMPA Raw Material 99% Nefiracetam Powder CAS 77191-36-7
The Introductction of Nefiracetam
Nefiracetam is a hydrophobic derivative of piracetam and is synthesized synthetically from all the Racetam compounds piracetam. Nefecitant is mainly produced by DaiichiSankyo (Japanese pharmaceutical company) for the treatment of Alzheimer's disease. In addition to all the mechanisms attributed to Nefiracetam, it is usually considered a substance that is found in calcium channels in vivo, as well as stimulating the indirect transfer of signaling substances as a partial agonist of the glycine binding site of the NDMA receptor.
Nefiracetam is a cognitive enhancer of the Racetam family, originally derived from the parent molecule piracetam, but most similar in structure to aniracetam. This is because nefecitam and aniracetam are lipid-soluble drugs. They are used in the treatment of memory improvement and cognitive impairment.
There are two mechanisms of action of Nefiracetam:
The first way is to prolong the opening of calcium channels (which bind to PKA and Gi/o proteins) that enhance the receptor response, regardless of the synapse .
The second way is a second pathway associated with PKC and CAMKII, whose response is completed due to cholinergic receptors (and then the most excitatory neurotransmitters released at the presynaptic level, as in the case of nicotine).
The previous pathway (calcium channels) is important in the long term, while the latter pathway (PKC/CAMKII) has an impact on the enhancement of neural signals and their transmission. Some other minor modalities can be partial agonists of NDMA receptors bound to glycine (which can enhance the interaction of certain levels of glycine, thus weakening the interaction), as well as increasing its communication with the ligand acetylcholine muscarinic acetylcholine receptor.
Nefiracetam is used for the treatment of cerebrovascular diseases. It can enhance cognition and prevent impairment of learning and memory by acting on the cerebral cortex. It does not have the properties of muscarinic receptor agonist and antagonist, nor does it inhibit acetylcholinesterase activity, so its antiamnesic and memory-enhancing effects occur by increasing the release of acetylcholine from the cerebral cortex.
|ITEMS OF ANALYSIS||SPECIFICATION||RESULT|
|Appearance||White crystalline powder||Conforms|
|Loss on drying||≤1.0%||0.30%|
|Residue on Ignition||≤0.1%||0.08%|
|Conclusion||Conform with the standard|